Comment by
scarlet1967 on Oct 20, 2021 9:22am
https://www.gazzettaufficiale.it/eli/id/2021/10/19/21A06097/SG
Comment by
scarlet1967 on Oct 20, 2021 9:24am
"packaging: «200 mg - concentrate for solution for infusion - intravenous use - vial (glass) - 1.33 ml (150 mg / ml) »2 vials - AIC n. 048255018 / E (base 10); reimbursement class: H; ex factory price (excluding VAT): euro 2,000.00; retail price (VAT included): € 3,300.80.”
Comment by
Wino115 on Oct 20, 2021 9:48am
I think we can go with Paul's "...it was a good price..." ! Certainly not US levels, but probably not below 50%. It had always sounded to me like they thought they could get 75-80% of US price and the Viiv product provided a bit of an umbrella to that as well.
Comment by
SPCEO1 on Oct 20, 2021 3:21pm
I should have noted that the always questionable sales estimator from Bloomberg shows US Trogarzo sales picked up a little in September while Egrifta sales slipped from August's level.